CMPX vs CNC · $367.4M cap vs P/E 8.4, rev $163.07B
Compass Therapeutics Inc. (CMPX) versus Centene Corp (CNC) — a side-by-side from cached financials, not a winner call.
Compass Therapeutics Inc. (CMPX) is a biotechnology company listed on US.
Centene Corp (CNC) is a healthcare plans company listed on US.
CMPX does not have a complete income-statement cache yet.
Latest reported CNC revenue for 2024-12-31 was $163.07B. Net income was $3.29B. Revenue was up 5.9% from 2023-12-31 to 2024-12-31. CNC currently screens at market cap $28.19B and trailing P/E 8.4.
CMPX currently screens at market cap $367.4M. CNC currently screens at market cap $28.19B and trailing P/E 8.4.
Not investment advice. Open the CMPX and CNC stock pages for the full models.
Not investment advice.